Clinical trials: Multiple Sclerosis
Autoimmune Diseases, Relapsing Multiple Sclerosis
Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
The proposed randomized, open label, with treat as usual control group (standard treatment or any disease modifying drugs), crossover phase II study will be conducted in 40 patients (n=20 per group) with the relapsing forms of…
- Trial name
- NCT03183869
- Testing
- Fecal microbiota
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
The purpose of this study is to characterize the central auditory processing (CAP) deficits that result from multiple sclerosis (MS).
- Trial name
- NCT01023074
- Testing
- Auditory training, MS: Control Activity
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis (MS)
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
The purpose of this study is to evaluate the safety, tolerability, kinetics, biodistribution and central nervous system signal of 11C-BMS-986196 after intravenous (IV) administration in healthy participants and after repeat IV…
- Trial name
- NCT05064436
- Testing
- 11C-BMS-986196
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Relapsing Remitting Multiple Sclerosis
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
- Trial name
- NCT02258217
- Testing
- Acthar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- OhioHealth
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono
Multiple Sclerosis
Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis
Cognitive impairment is common in MS and has devastating impact on functional activities. There is a great demand for medications that will enhance cognitive capacity in MS patients.
- Trial name
- NCT02651545
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis
Protective Stepping in People With MS
Falls are common in Veterans with multiple sclerosis (MS), and current rehabilitation approaches to reduce falls are inadequate.
- Trial name
- PRO-STEP (NCT03551665)
- Testing
- Protective step training
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Relapsing Remitting Multiple Sclerosis
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
The primary objective of this study was to assess the bioequivalence of the test product (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg based on the Cmax and Area Under the Curve…
- Trial name
- NCT04570670
- Testing
- monomethyl fumarate 190 mg, dimethyl fumarate 240 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis, Immune System Diseases
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
- Trial name
- NCT03344094
- Testing
- ocrelizumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hypertension, Heart Failure
LSFG-SKIN, Laser Speckle Flowgraphy
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or…
- Conditions
- Hypertension, Heart Failure, Vascular Ischemia, Burns
- Trial name
- NCT03660618
- Testing
- laser speckle flowgraphy
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Randy Kardon
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Traumatic Brain Injury, Multiple Sclerosis
Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging
This study will test a new MRI sequence that measures cerebral blood flow (CBF). Because this technique for measuring CBF is new, there is little information on what the normal values for different regions of the brain should be.
- Conditions
- Traumatic Brain Injury, Multiple Sclerosis, Alzheimer's Disease, Tumor
- Trial name
- NCT02767609
- Testing
- Magnetic Resonance Imaging
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Multiple Sclerosis
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple…
- Trial name
- NCT00246324
- Testing
- Interferon beta 1a, oral doxycycline
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
This was a Phase 2, randomized, double-blind, placebo-controlled 2 parallel-arm study to assess the effect on serum neurofilament light chain (sNfL), safety and tolerability of oral SAR443820 compared to placebo in male and…
- Trial name
- NCT05630547
- Testing
- SAR443820
- Where
- 35 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Sanofi